|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grubb RL III and Kibel AS: Prostate
cancer: Screening, diagnosis and management in 2007. Mo Med.
104:408–413; quiz 413–404. 2007.PubMed/NCBI
|
|
3
|
Feldman BJ and Feldman D: The development
of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bejarano PA, Noelken ME, Suzuki K, Hudson
BG and Nagase H: Degradation of basement membranes by human matrix
metalloproteinase 3 (stromelysin). Biochem J. 256:413–419. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pei D: Matrix metalloproteinases target
protease-activated receptors on the tumor cell surface. Cancer
Cell. 7:207–208. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Verma RP and Hansch C: Matrix
metalloproteinases (MMPs): Chemical-biological functions and
(Q)SARs. Bioorg Med Chem. 15:2223–2268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vihinen P and Kähäri VM: Matrix
metalloproteinases in cancer: Prognostic markers and therapeutic
targets. Int J Cancer. 99:157–166. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jäälinojä J, Herva R, Korpela M, Höyhtyä M
and Turpeenniemi-Hujanen T: Matrix metalloproteinase 2 (MMP-2)
immunoreactive protein is associated with poor grade and survival
in brain neoplasms. J Neurooncol. 46:81–90. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu N, Ling Y, Gao Y, Chen Y, Mu R, Qi Q,
Liu W, Zhang H, Gu H, Wang S, et al: Endostar suppresses invasion
through downregulating the expression of matrix
metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Exp
Biol Med (Maywood). 233:1013–1020. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang B, Tang F, Zhang B, Zhao Y, Feng J
and Rao Z: Matrix metalloproteinase-9 overexpression is closely
related to poor prognosis in patients with colon cancer. World J
Surg Oncol. 12:242014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gohji K, Fujimoto N, Hara I, Fujii A,
Gotoh A, Okada H, Arakawa S, Kitazawa S, Miyake H, Kamidono S and
Nakajima M: Serum matrix metalloproteinase-2 and its density in men
with prostate cancer as a new predictor of disease extension. Int J
Cancer. 79:96–101. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moses MA, Wiederschain D, Loughlin KR,
Zurakowski D, Lamb CC and Freeman MR: Increased incidence of matrix
metalloproteinases in urine of cancer patients. Cancer Res.
58:1395–1399. 1998.PubMed/NCBI
|
|
13
|
Takino T, Sato H, Shinagawa A and Seiki M:
Identification of the second membrane-type matrix metalloproteinase
(MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a
unique membrane-type subclass in the MMP family. J Biol Chem.
270:23013–23020. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lowy AM, Clements WM, Bishop J, Kong L,
Bonney T, Sisco K, Aronow B, Fenoglio-Preiser C and Groden J:
beta-Catenin/Wnt signaling regulates expression of the membrane
type 3 matrix metalloproteinase in gastric cancer. Cancer Res.
66:4734–4741. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakada M, Nakamura H, Ikeda E, Fujimoto N,
Yamashita J, Sato H, Seiki M and Okada Y: Expression and tissue
localization of membrane-type 1, 2 and 3 matrix metalloproteinases
in human astrocytic tumors. Am J Pathol. 154:417–428. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tatti O, Arjama M, Ranki A, Weiss SJ,
Keski-Oja J and Lehti K: Membrane-type-3 matrix metalloproteinase
(MT3-MMP) functions as a matrix composition-dependent effector of
melanoma cell invasion. PLoS One. 6:e283252011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Y, Wang Y, Yu L, Sun C, Cheng D, Yu S,
Wang Q, Yan Y, Kang C, Jin S, et al: miR-146b-5p inhibits glioma
migration and invasion by targeting MMP16. Cancer Lett.
339:260–269. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hotary K, Allen E, Punturieri A, Yana I
and Weiss SJ: Regulation of cell invasion and morphogenesis in a
three-dimensional type I collagen matrix by membrane-type matrix
metalloproteinases 1, 2 and 3. J Cell Biol. 149:1309–1323. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferraro GB, Morrison CJ, Overall CM,
Strittmatter SM and Fournier AE: Membrane-type matrix
metalloproteinase-3 regulates neuronal responsiveness to myelin
through Nogo-66 receptor 1 cleavage. J Biol Chem. 286:31418–31424.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koc M, Ediger D, Budak F, Karadağ M, Oral
HB, Uzaslan E, Ege E and Gözü RO: Matrix metalloproteinase-9
(MMP-9) elevated in serum but not in bronchial lavage fluid in
patients with lung cancer. Tumori. 92:149–154. 2006.PubMed/NCBI
|
|
21
|
Kuhlmann KF, van Till JW, Boermeester MA,
de Reuver PR, Tzvetanova ID, Offerhaus GJ, Ten Kate FJ, Busch OR,
van Gulik TM, Gouma DJ and Crawford HC: Evaluation of matrix
metalloproteinase 7 in plasma and pancreatic juice as a biomarker
for pancreatic cancer. Cancer Epidemiol Biomarkers Prev.
16:886–891. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Poola I, DeWitty RL, Marshalleck JJ,
Bhatnagar R, Abraham J and Leffall LD: Identification of MMP-1 as a
putative breast cancer predictive marker by global gene expression
analysis. Nat Med. 11:481–483. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sauer CG, Kappeler A, Späth M, Kaden JJ,
Michel MS, Mayer D, Bleyl U and Grobholz R: Expression and activity
of matrix metalloproteinases-2 and −9 in serum, core needle
biopsies and tissue specimens of prostate cancer patients. Virchows
Arch. 444:518–526. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tetu B, Brisson J, Wang CS, Lapointe H,
Beaudry G, Blanchette C and Trudel D: The influence of MMP-14,
TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast
Cancer Res. 8:R282006. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wood M, Fudge K, Mohler JL, Frost AR,
Garcia F, Wang M and Stearns ME: In situ hybridization studies of
metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in
human prostate cancer. Clin Exp Metastasis. 15:246–258. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD,
Yang F and Xu XC: Prognostic significance of MMP-9 and TIMP-1 serum
and tissue expression in breast cancer. Int J Cancer.
122:2050–2056. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nagakawa O, Murakami K, Yamaura T,
Fujiuchi Y, Murata J, Fuse H and Saiki I: Expression of
membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate
cancer cell lines. Cancer Lett. 155:173–179. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ota I, Li XY, Hu Y and Weiss SJ: Induction
of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration
program in cancer cells by Snail1. Proc Natl Acad Sci USA.
106:20318–20323. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sato H, Takino T and Miyamori H: Roles of
membrane-type matrix metalloproteinase-1 in tumor invasion and
metastasis. Cancer Sci. 96:212–217. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Daja MM, Niu X, Zhao Z, Brown JM and
Russell PJ: Characterization of expression of matrix
metalloproteinases and tissue inhibitors of metalloproteinases in
prostate cancer cell lines. Prostate Cancer Prostatic Dis. 6:15–26.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moon JW, Choi JH, Lee SK, Lee YW, Lee JO,
Kim N, Lee HJ, Seo JS, Kim J, Kim HS, et al: Promoter
hypermethylation of membrane type 3 matrix metalloproteinase is
associated with cell migration in colorectal adenocarcinoma. Cancer
Genet. 208:261–270. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tatti O, Gucciardo E, Pekkonen P,
Holopainen T, Louhimo R, Repo P, Maliniemi P, Lohi J, Rantanen V,
Hautaniemi S, et al: MMP16 mediates a proteolytic switch to promote
cell-cell adhesion, collagen alignment, and lymphatic invasion in
melanoma. Cancer Res. 75:2083–2094. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang H, Li XT, Wu C, Wu ZW, Li YY, Yang
TQ, Chen GL, Xie XS, Huang YL, Du ZW and Zhou YX: miR-132 can
inhibit glioma cells invasion and migration by target MMP16 in
vitro. Onco Targets Ther. 8:3211–3218. 2015.PubMed/NCBI
|
|
34
|
Sato H and Seiki M: Membrane-type matrix
metalloproteinases (MT-MMPs) in tumor metastasis. J Biochem.
119:209–215. 1996. View Article : Google Scholar : PubMed/NCBI
|
